Screener
Arcus Biosciences RCUS License — Total revenues
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Arcus Biosciences in its filing.
Tagged under the XBRL concept us-gaap:Revenues.
The source filing: Arcus Biosciences’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:11 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001724521-26-000044
| Line item | Over time | Point in time | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|---|---|
| Access rights | * | 21 | 6 | 24 | 11 | |
| Other | * | — | — | 3 | — | |
| Taiho Collaboration | ||||||
| License and development services | * | 4 | — | 6 | — | |
| License | * | 4 | — | 4 | — | |
| Total revenues | $41 | $160 | $58 | $188 | ||
| Total revenues from collaborations | $8 | $152 | $18 | $172 | ||
| Total revenues from a customer | $33 | $8 | $40 | $16 |
Item 1. Financial Statements
FAQ
- What is Arcus Biosciences's license — total revenues?
- Arcus Biosciences (RCUS) reported license — total revenues of $4M in Q2 2026.
- What does license — total revenues mean?
- This metric represents the total revenue recognized from licensing agreements, including upfront payments, milestone payments, and royalties derived from intellectual property. It reflects the company's ability to monetize its research and development pipeline through strategic partnerships with other biopharmaceutical entities. This revenue stream is a critical indicator of the commercial viability and market interest in the company's proprietary therapeutic candidates.
Ask your AI about Arcus Biosciences's license — total revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude